Case Western Reserve University (CWRU) has granted an exclusive licence to biofirm spinoff ReXceptor to develop an Alzheimer’s Disease (AD) treatment.
Originally approved by the Food and Drug Administration to treat T-cell lumphomas, CWRU research discovered that bexarotene (trademarked as Targretin) also reversed symptoms of AD in mice within 72 hours following a single dose. The findings, published in journal Science, went on to attract widespread media attention.
To date, ReXceptor has secured $1.4m to continue its work. $500k was…
